Published in Am J Transplant on January 22, 2007
Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs (2011) 1.24
Cyclosporine: a review. J Transplant (2012) 1.11
Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol (2008) 1.06
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol (2011) 1.04
Recent developments in kidney transplantation--a critical assessment. Am J Transplant (2009) 1.02
Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. J Am Soc Nephrol (2015) 1.01
Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant (2011) 0.98
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics (2009) 0.93
Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol (2008) 0.93
The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept. Biologics (2007) 0.87
Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant (2013) 0.86
Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol (2013) 0.84
Tacrolimus inhibits NF-κB activation in peripheral human T cells. PLoS One (2013) 0.83
Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. J Transl Med (2014) 0.80
Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int (2016) 0.78
Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. Transpl Int (2012) 0.77
Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability. Ther Clin Risk Manag (2009) 0.76
Lessons from the CAESAR Study: calcineurin inhibitors--can't live with them and can't live without them. Am J Transplant (2007) 0.76
Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids. Nat Clin Pract Nephrol (2007) 0.75
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant (2012) 0.75
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up. J Transplant (2010) 0.75
Symptomatic lymphocele developing soon after acute renal allograft rejection: coincidental or causal connection? Clin Kidney J (2013) 0.75
Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmgenomics Pers Med (2012) 0.75
The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors. Arab J Urol (2012) 0.75
Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol (2014) 0.75
A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation. Curr Urol (2014) 0.75
Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. Transpl Int (2009) 0.75
Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation. Yonsei Med J (2017) 0.75
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 4.41
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther (2012) 3.51
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Tolerance versus immunosuppression: a perspective. Am J Transplant (2008) 2.71
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int (2006) 2.64
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 2.46
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 2.39
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 2.27
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet (2000) 2.26
Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group. N Engl J Med (1992) 2.17
Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant (2012) 2.10
Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet (1990) 2.04
Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation (1995) 2.03
Predicting microbial growth: the consequences of quantity of data. Int J Food Microbiol (1989) 2.01
Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant (2007) 1.97
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant (2011) 1.90
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int (2006) 1.90
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant (2009) 1.88
Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int (2008) 1.85
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.78
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers. Transplantation (2000) 1.46
Cognitive performance in pediatric liver transplant recipients. Am J Transplant (2013) 1.46
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant (2006) 1.45
Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg (1980) 1.45
Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy (1996) 1.44
A ten year experience with cadaver kidney preservation using cryoprecipitated plasma. Am J Surg (1978) 1.44
The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation (1995) 1.43
Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant (2012) 1.42
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther (1998) 1.42
Detrimental effects of ocean acidification on the economically important Mediterranean red coral (Corallium rubrum). Glob Chang Biol (2013) 1.41
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol (1999) 1.38
Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation (1998) 1.35
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant (2008) 1.33
Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant (2007) 1.32
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant (2010) 1.31
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27
Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation (1999) 1.27
Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med (1992) 1.24
A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol (2001) 1.23
Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant (2013) 1.23
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther (2007) 1.23
Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis (1994) 1.18
A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation (1985) 1.17
Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol (1998) 1.17
Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation (1999) 1.16
Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation (1997) 1.15
Transcatheter embolization of biopsy-related vascular injuries in renal allografts. Long-term technical, clinical and biochemical results. Acta Radiol (2003) 1.12
High prevalence of hepatitis G virus infection compared with hepatitis C virus infection in patients undergoing chronic hemodialysis. Am J Kidney Dis (1998) 1.12
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc (1998) 1.10
Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit (2003) 1.10
Ovarian-like stroma in an invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin. A hint concerning its possible histogenesis. Virchows Arch (1998) 1.09
Effect of a presumed consent law on organ retrieval in Belgium. Transplant Proc (1990) 1.07
[Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol (2011) 1.07
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant (2006) 1.07
Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant (1996) 1.05
Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant (2007) 1.05
FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. Transplant Proc (1997) 1.03
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant (2009) 1.02
Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant (2007) 1.02
Persistence of donor lymphocytes in liver allograft recipients. Transplantation (1993) 1.02
Images in Nephrology. Renal cortical nephrocalcinosis. Nephrol Dial Transplant (2000) 1.01
Legislative aspects of organ and tissue donation in Belgium. Ann Transplant (1996) 1.00
Severe alport phenotype in a woman with two missense mutations in the same COL4A5 gene and preponderant inactivation of the X chromosome carrying the normal allele. J Clin Invest (1995) 1.00
The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med (1980) 1.00
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant (2005) 1.00
Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc (1999) 0.99
Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci (2005) 0.97
Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival. N Engl J Med (1978) 0.97
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant (2009) 0.95
Three years of experience with a 'presumed consent' legislation in Belgium: its impact on multi-organ donation in comparison with other European countries. The Leuven Collaborative Group for Transplantation. Transplant Proc (1991) 0.95
Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 0.94
The management of the failed renal allograft. Nephrol Dial Transplant (1996) 0.94
The relative impact of legislative incentives on multi-organ donation rates in Europe. Transplant Proc (1995) 0.93
Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant (2013) 0.93
Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects. Transplantation (1983) 0.93
Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol (1994) 0.93
Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol (1991) 0.93
Deaths within 90 days from starting renal replacement therapy in the ERA-EDTA Registry between 1990 and 1992. Nephrol Dial Transplant (1999) 0.92
Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int (2006) 0.92
Extramedullary erythropoiesis in human liver grafts. Hepatology (1995) 0.91
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation (2001) 0.91
Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc (2002) 0.91
Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology (1998) 0.90
Delusional depression: phenomenology and response to treatment. A prospective study. Acta Psychiatr Scand (1986) 0.90
Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months. Transplant Proc (1986) 0.90